Thomas Tedder

Thomas Fletcher Tedder, Ph.D., (born May 14, 1956) is an American immunologist. He is best known for his work in the fields of B lymphocyte biology and regulation. He is currently the Alter E. Geller Professor for Research in Immunology at Duke University. [1]

Career

Tedder received his Ph.D. in molecular cell biology from the University of Alabama at Birmingham in 1984 and completed his postdoctoral training as a Research Fellow in Pathology at Harvard Medical School. He was a faculty member at Dana-Farber Cancer Institute and Harvard Medical School from 1985 to 1998 before joining Duke University in 1993 as its founding Chairman of Immunology. [2] Tedder studies the structure and function of B lymphocyte cell surface molecules that regulate B cell function, activation, and signal transduction. He currently has 401 total publications and 25 issued patents relating to B cells and their products, including CD19, CD20, CD22, CD83, and L-selectin.[3] He has founded three biotherapeutic companies, including Angelica Therapeutics, Cellective Therapeutics, and most recently, Cellective BioTherapy. [4]

References

  1. ↑ Duke University profile
  2. ↑ http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=8410861
  3. ↑ http://angelicatherapeutics.com/founders.html
  4. ↑ http://www.bizjournals.com/triangle/news/2015/06/12/fred-eshelman-invests-cellective-biotherapy-duke.html
This article is issued from Wikipedia - version of the Tuesday, October 20, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.